1. Home
  2. VLTO vs BIIB Comparison

VLTO vs BIIB Comparison

Compare VLTO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veralto Corp

VLTO

Veralto Corp

HOLD

Current Price

$100.75

Market Cap

24.5B

Sector

Industrials

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$170.66

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLTO
BIIB
Founded
2023
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
VLTO
BIIB
Price
$100.75
$170.66
Analyst Decision
Buy
Buy
Analyst Count
9
22
Target Price
$113.25
$177.40
AVG Volume (30 Days)
1.8M
2.0M
Earning Date
02-03-2026
10-30-2025
Dividend Yield
0.52%
N/A
EPS Growth
12.64
N/A
EPS
3.65
10.97
Revenue
$5,452,000,000.00
$10,065,900,000.00
Revenue This Year
$8.28
$3.61
Revenue Next Year
$5.83
N/A
P/E Ratio
$27.41
$15.68
Revenue Growth
6.15
4.77
52 Week Low
$83.87
$110.04
52 Week High
$110.11
$185.17

Technical Indicators

Market Signals
Indicator
VLTO
BIIB
Relative Strength Index (RSI) 52.73 48.08
Support Level $98.42 $169.52
Resistance Level $101.08 $175.94
Average True Range (ATR) 1.76 5.18
MACD 0.07 -1.98
Stochastic Oscillator 54.67 12.20

Price Performance

Historical Comparison
VLTO
BIIB

About VLTO Veralto Corp

Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: